Insight Molecular Diagnostics
IMDX
27 hedge funds and large institutions have $20M invested in Insight Molecular Diagnostics in 2024 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 0 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
50% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 6
29% more funds holding
Funds holding: 21 → 27 (+6)
2% less capital invested
Capital invested by funds: $20.4M → $20M (-$395K)
3.63% less ownership
Funds ownership: 53.6% → 49.97% (-3.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadwood Capital
New York
|
+$3.58M |
| 2 |
PVI
Pura Vida Investments
New York
|
+$432K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$89.9K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$35.9K |
| 5 |
GSC
Ground Swell Capital
Folly Beach,
South Carolina
|
+$29.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIC
AWM Investment Company
New York
|
-$873K |
| 2 |
DC
Defender Capital
Charlotte,
North Carolina
|
-$33.4K |
| 3 |
Morgan Stanley
New York
|
-$28.8K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$8.65K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$2.44K |
IMDX Hedge Fund Activity: Q4 2024 in Review
27 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Insight Molecular Diagnostics (IMDX) for Q4 2024, worth a combined $20M — down 1.9% from $20.4M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new IMDX positions and 0 closed out — a net gain of 6 holders — while 9 added to existing stakes and 6 trimmed.
The largest buyer was Broadwood Capital, adding an estimated $3.58M. The largest seller was AWM Investment Company, cutting an estimated $873K.
- 27 institutional investors held Insight Molecular Diagnostics (IMDX) as of Q4 2024, up from 21 in Q3 2024.
- Funds reported $20M of Insight Molecular Diagnostics stock for Q4 2024, down 1.9% quarter-over-quarter.
- 6 funds opened new Insight Molecular Diagnostics positions in Q4 2024 and 0 closed out, a net change of +6 holders.
- The largest Insight Molecular Diagnostics buyer in Q4 2024 was Broadwood Capital, an estimated $3.58M added.
- The largest Insight Molecular Diagnostics seller in Q4 2024 was AWM Investment Company, an estimated $873K sold.
Based on aggregated 13F filings for Q4 2024.